Intro to Cognitive Neuroscience

Alzheimer's disease

Dementia

• A family of diseases that are characterized by cognitive and behavioral deficits involving some sort of permanent damage to the brain.

Dementias affect ~4 million people in the U.S. (6% - 8% of people over age
 65)

Alzheimer's disease

- First described in 1907 by Alois Alzheimer as "a strange disease of the cerebral cortex".
- Accounts for 50% 70% of all dementias.

AD diagnostic criteria

- Multiple cognitive deficits, including
 - Memory impairment
 - At least one of: aphasia, apraxia, agnosia, or disturbance in executive function.

AD diagnostic criteria

• Significant impairment in functioning, involving a decline from previous level.

Gradual onset and continuing cognitive decline.

AD diagnostic criteria

• Requires neurological evidence (from autopsy) for a definitive diagnosis




Image courtesy of the National Institute on Aging

Normal vs. AD brain - some macro scale differences

- Two characteristic changes at the cellular level:
- Senile plaques made up of small (35 40 amino acids) peptide fragments called amyloid-beta.




Image courtesy of the National Institute on Aging

A-beta plaques





Image courtesy of the National Institute on Aging

- Two characteristic changes at the cellular level:
- Neurofibrillary tangles tau proteins associated with the cytoskeleton.
 - Tau proteins become hyperphosphorylated and change shape, causing microtubules to disintegrate.



Neurofibrillary Tangles

Image courtesy of the National Institute on Aging

- Two characteristic changes at the cellular level:
- Tau tangles proteins associated with the cytoskeleton.




Image courtesy of the National Institute on Aging

 Senile plaques and neurofibrillary tangles are characteristic of normal aging, but AD patients have more and in different locations.

• Both of these are protein-misfolding issues, so AD is classified as a proteopathy.

- Unknown, but some hypotheses:
 - Cholinergic hypothesis AD is caused by reduced synthesis of ACh.
 - Most medications for AD are based on this hypothesis; treat symptoms but do not affect progression of disease.

- Tau hypothesis tau protein abnormalities trigger the disease.
 - Supported by flaws in amyloid hypothesis, mostly.

- · Amyloid hypothesis amyloid-beta deposits are causative factor.
 - Majority of researchers support this hypothesis.
 - Gene for APP is on chromosome 21 (chromosome that is tripled in Down syndrome, and DS patients almost always exhibit AD-like symptoms by age 40).

- Amyloid hypothesis amyloid-beta deposits are causative factor.
 - Study by Holmes et al (2008). Stage 1 Clinical trial of a vaccine that removes amyloid-beta plaques.
 - Found no improvement in survival rates or dementia progression, despite effectiveness at clearing plaques.

MIT OpenCourseWare http://ocw.mit.edu

Introduction to Cognitive Neuroscience Summer 2008

For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.